WO2018005444A3 - Methods for treating cancer - Google Patents

Methods for treating cancer Download PDF

Info

Publication number
WO2018005444A3
WO2018005444A3 PCT/US2017/039430 US2017039430W WO2018005444A3 WO 2018005444 A3 WO2018005444 A3 WO 2018005444A3 US 2017039430 W US2017039430 W US 2017039430W WO 2018005444 A3 WO2018005444 A3 WO 2018005444A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
foregoing
treating cancer
compounds
formula
Prior art date
Application number
PCT/US2017/039430
Other languages
French (fr)
Other versions
WO2018005444A2 (en
Inventor
Chiang Jia Li
Matthew HITRON
Youzhi Li
Wei Li
Waldo ORTUZAR
Original Assignee
Boston Biomedical, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Biomedical, Inc. filed Critical Boston Biomedical, Inc.
Priority to CA3029596A priority Critical patent/CA3029596A1/en
Priority to JP2018568329A priority patent/JP2019519573A/en
Publication of WO2018005444A2 publication Critical patent/WO2018005444A2/en
Publication of WO2018005444A3 publication Critical patent/WO2018005444A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Methods comprising administering and kits comprising a therapeutically effective amount of at least one first compound chosen from compounds having Formula A: and compounds having Formula B: prodrugs thereof, derivatives thereof, pharmaceutically acceptable salts of any of the foregoing, and solvates of any of the foregoing; and a therapeutically effective amount of at least one second compound chosen from compounds having Formula C: prodrugs thereof, derivatives thereof, pharmaceutically acceptable salts of any of the foregoing, and solvates of any of the foregoing.
PCT/US2017/039430 2016-06-28 2017-06-27 Methods for treating cancer WO2018005444A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA3029596A CA3029596A1 (en) 2016-06-28 2017-06-27 Methods for treating cancer
JP2018568329A JP2019519573A (en) 2016-06-28 2017-06-27 Methods for treating cancer

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662355410P 2016-06-28 2016-06-28
US62/355,410 2016-06-28
US201762506929P 2017-05-16 2017-05-16
US62/506,929 2017-05-16
US201762514059P 2017-06-02 2017-06-02
US62/514,059 2017-06-02

Publications (2)

Publication Number Publication Date
WO2018005444A2 WO2018005444A2 (en) 2018-01-04
WO2018005444A3 true WO2018005444A3 (en) 2018-02-15

Family

ID=59325662

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/039430 WO2018005444A2 (en) 2016-06-28 2017-06-27 Methods for treating cancer

Country Status (4)

Country Link
JP (1) JP2019519573A (en)
CA (1) CA3029596A1 (en)
TW (1) TW201806592A (en)
WO (1) WO2018005444A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3765402A4 (en) * 2018-03-16 2021-11-17 The Board of Trustees of the Leland Stanford Junior University Analysis of response to therapeutics in cancer
CN112955143B (en) * 2018-09-18 2023-10-13 北京强新生物科技有限公司 Treatment of non-alcoholic fatty liver disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009036099A1 (en) * 2007-09-10 2009-03-19 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
WO2016176190A1 (en) * 2015-04-27 2016-11-03 Boston Biomedical, Inc. Methods for treating cancer with a stat3 pathway inhibitor and kinase inhibitor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010537640A (en) 2007-08-27 2010-12-09 ボストン バイオメディカル， インコーポレイテッド Compositions of asymmetric RNA duplexes as microRNA mimetics or inhibitors
CN101848908B (en) 2007-09-06 2014-07-02 北京强新生物科技有限公司 Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases
WO2011116399A1 (en) 2010-03-19 2011-09-22 Boston Biomedical, Inc. Novel methods for targeting cancer stem cells
RU2571661C2 (en) 2010-03-19 2015-12-20 Бостон Байомедикал, Инк. Novel compounds and compositions for targeting at malignant stem cells
CN103402993A (en) 2011-03-04 2013-11-20 舟山海中洲新生药业有限公司 Novel esters of 4,9-dihydroxy-naphtho[2,3-b]furans for disease therapies
US8977803B2 (en) 2011-11-21 2015-03-10 Western Digital Technologies, Inc. Disk drive data caching using a multi-tiered memory
AU2014243869A1 (en) 2013-03-13 2015-09-24 Boston Biomedical, Inc. 3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer
US20160030384A1 (en) 2013-04-09 2016-02-04 Boston Biomedical, Inc. 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009036099A1 (en) * 2007-09-10 2009-03-19 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
WO2016176190A1 (en) * 2015-04-27 2016-11-03 Boston Biomedical, Inc. Methods for treating cancer with a stat3 pathway inhibitor and kinase inhibitor

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ANDRE LUIZ MENCALHA ET AL: "LLL-3, a STAT3 inhibitor, represses BCR-ABL-positive cell proliferation, activates apoptosis and improves the effects of Imatinib mesylate", CANCER CHEMOTHERAPY AND PHARMACOLOGY, SPRINGER, BERLIN, DE, vol. 65, no. 6, 23 August 2009 (2009-08-23), pages 1039 - 1046, XP019800774, ISSN: 1432-0843 *
ANONYMOUS: "Meeting Library | BBI608-503-103HCC: A phase Ib/II clinical study of napabucasin (BBI608) in combination with sorafenib or amcasertib (BBI503) in combination with sorafenib (Sor) in adult patients with hepatocellular carcinoma (HCC).", 3 June 2017 (2017-06-03), XP055414246, Retrieved from the Internet <URL:http://meetinglibrary.asco.org/record/147826/abstract> [retrieved on 20171010] *
ANONYMOUS: "NCT02279719 on 2016_06_27: ClinicalTrials.gov Archive", 27 June 2016 (2016-06-27), XP055414262, Retrieved from the Internet <URL:https://clinicaltrials.gov/archive/NCT02279719/2016_06_27> [retrieved on 20171010] *
DONG-XIAN GUAN ET AL: "Sorafenib Enriches Epithelial Cell Adhesion Molecule-Positive Tumor Initiating Cells and Exacerbates a Subtype of Hepatocellular Carcinoma Through TSC2-AKT Cascade", SHANGHAI INSTITUTES FOR BIOLOGICAL SCIENCES CHINESE ACADEMY OF SCIENCES, 24 October 2015 (2015-10-24), pages 2012 - 10002009, XP055414631, Retrieved from the Internet <URL:http://onlinelibrary.wiley.com/store/10.1002/hep.28117/asset/hep28117.pdf?v=1&t=j8mywk8u&s=48ba1616c311b77426bc5bc07516bf2c72a5e282> [retrieved on 20171011], DOI: 10.1002/hep.28117/suppinfo *
LLOVET J M ET AL: "Sorafenib in advanced hepatocellular carcinoma", NEW ENGLAND JOURNAL OF MEDICINE, THE - NEJM -, MASSACHUSETTS MEDICAL SOCIETY, US, vol. 359, no. 4, 24 July 2008 (2008-07-24), pages 378 - 390, XP009185548, ISSN: 0028-4793, DOI: 10.1056/NEJMOA0708857 *
YOUZHI LI ET AL: "Suppression of cancer relapse and metastasis by inhibiting cancer stemness", PROCEEDINGS NATIONAL ACADEMY OF SCIENCES PNAS, vol. 112, no. 6, 20 January 2015 (2015-01-20), US, pages 1839 - 1844, XP055283316, ISSN: 0027-8424, DOI: 10.1073/pnas.1424171112 *

Also Published As

Publication number Publication date
CA3029596A1 (en) 2018-01-04
TW201806592A (en) 2018-03-01
JP2019519573A (en) 2019-07-11
WO2018005444A2 (en) 2018-01-04

Similar Documents

Publication Publication Date Title
CY1124652T1 (en) 1H-INDAZOLE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR D INHIBITORS FOR THE TREATMENT OF DISEASES CHARACTERIZED BY ABNORMAL ACTIVITY OF THE COMPLEMENT SYSTEM, SUCH AS E.G. IMMUNOLOGICAL DISORDERS
WO2017075629A3 (en) Wee 1 kinase inhibitors and methods of making and using the same
MX2021014531A (en) Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith.
WO2019169065A3 (en) Wee1 kinase inhibitors and methods of treating cancer using the same
MX2022014864A (en) Bisamide sarcomere activating compounds and uses thereof.
MX2021011606A (en) Compounds targeting prmt5.
WO2017067530A3 (en) Combination treating prostate cancer, pharmaceutical composition and treatment method
ZA202100485B (en) Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
MX2022006783A (en) New methylquinazolinone derivatives.
EA202193015A1 (en) CDK INHIBITORS
WO2019204505A3 (en) K-ras modulators with a vinyl sulfonamide moiety
PH12017501882A1 (en) Methods for treating cancer with a stat3 pathway inhibitor and kinase inhibitor
MX2021012105A (en) Pyrrole compounds.
MX2021007247A (en) Rapamycin derivatives.
WO2018039077A8 (en) Therapeutic compounds
PH12019550154A1 (en) Azetidine derivative
MX2022007626A (en) Combinations.
MX2022007628A (en) Combinations.
MX2021007258A (en) Amorphous sparsentan compositions.
WO2018005444A3 (en) Methods for treating cancer
PH12021550452A1 (en) Methods of treating mycobacterial infections using tetracycline compounds
MX2021009717A (en) Bicyclic sulfonamides.
WO2017095950A3 (en) Compounds for treating proliferative diseases
MX2021014458A (en) Tricyclic compounds.
MX2022007625A (en) Combinations.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17739417

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2018568329

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 3029596

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17739417

Country of ref document: EP

Kind code of ref document: A2